Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is conducted to determine the safety, tolerability, pharmacokinetics and
anti-tumor activity of HS-10241 when given together with Almonertinib in patients with EGFRm+
advanced NSCLC.